Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IL-13 inhibitor

- PMLiVE

GSK first to file IL-5 antagonist for asthma

Mepolizumab submitted as a treatment for severe eosinophilic asthma

- PMLiVE

Successful partnerships in pharma: Skyepharma and Mundipharma

Why skills and flexibility matter more than sheer size

AZ launches breast cancer photo-sharing campaign

Social media campaign will see a selection of the pictures displayed in New York

Sanofi reception

Trial suggests Sanofi’s asthma drug works in sinusitis

Dupilumab able to reduce polyp size in sinusitis patients

- PMLiVE

Boehringer’s Spiriva cleared for asthma in EU

Drug approved as a treatment for adults with severe asthma

- PMLiVE

Teva stakes its claim to the asthma antibody market

Plans to file reslizumab early next year

- PMLiVE

AZ takes asthma antibody into phase III

Tralokinumab tipped as potential blockbuster

- PMLiVE

AZ licenses asthma infection drug from Synairgen

Boosts respiratory portfolio with $232m deal

- PMLiVE

GSK set to file severe asthma candidate by year-end

Mepolizumab reduces frequency of exacerbations in late-stage trial

- PMLiVE

AZ takes severe asthma antibody into phase III

Benralizumab shows promise in clinical trials

- PMLiVE

FDA guidance clears path for Advair generics

Offers simplified process for potential copies of GSK’s asthma and COPD drug

- PMLiVE

Meda buys US respiratory firm Acton in $200m deal

Swedish pharma firm gains access to asthma treatment Aerospan

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links